

Symbol	Name	Protein Classification	Feature Importance		Known/plausible in DILI?	Citation(s)
			RF	SVM		
ADORA1	Adenosine A1 receptor	GPCR	0.00384	-0.47612	Involvement in protection against DILI for ADORA2 - Putative novel target?	Chiang, D.J. et al. (2013) ¹
AKR1B1	Aldose reductase	Oxidoreductases	0.00447	0.28545	Oxidative stress and apoptosis	Ahmed, M.M. et al. (2016) ²
AKR1C2	Aldo-keto reductase family 1 member C2	Oxidoreductases	0.00244	-0.01159	Drug metabolism, Phase II Reaction	Barski, O.A. et al. (2008) ³ ; Chen, W.D. et al. (2012) ⁴
AKR1C3	Aldo-keto-reductase family 1 member C3	Oxidoreductases	0.00441	0.48452	Drug metabolism, Phase II Reaction	Barski, O.A. et al. (2008) ³ ; Chen, W.D. et al. (2012) ⁴
APBA1	Voltage-gated N-type calcium channel alpha-1B subunit/Amyloid beta A4 precursor protein-binding family A member 1	Transporter	0.00542	0.04074	No Involvement in DILI	
AR	Androgen Receptor	NHR	0.00063	0.39500	Sex discrepancy in DILI	Sutti, S. et al. (2018) ⁵
C1R	Complement C1r	Protease	0.00548	0.02562	No Involvement in DILI	
CCNB2	Cyclin-dependent kinase 1/cyclin B2	Other	0.00097	0.35835	Overexpressed during liver regeneration	Lu, X.P. et al.(1992) ⁶
CCNB3	Cyclin-dependent kinase 1/cyclin B3	Other	0.00076	0.35835	No Involvement in DILI	
CDC25A	Dual specificity phosphatase Cdc25A	Phosphatase	0.00067	0.32319	Overexpressed in hepatocellular carcinoma cells	Xundi, X. et al. (2003) ⁷
CLK1	Dual specificity protein kinase CLK1	Kinase	0.00841	0.08904	No Involvement in DILI	
CSNK2A2	Casein kinase II alpha (prime)	Kinase	0.00285	0.01077	No Involvement in DILI	
CXCR2	Interleukin-8 receptor B	GPCR	0.00209	0.38108	Activation in patients with chronic liver diseases	Zimmermann, H.W. et al. (2011) ⁸
CYP19A1	Cytochrome P450 19A1	Oxidoreductases	0.00128	0.45375	No Involvement in DILI	
CYP1A2	Cytochrome P450 1A2	Oxidoreductases	0.00193	0.43226	Drug metabolism, high expression in liver	Zanger, U.M. et al. (2013) ⁹
CYP2C9	Cytochrome P450 2C9	Oxidoreductases	0.00241	0.42051	Drug metabolism, high expression in liver	Zanger, U.M. et al. (2013) ⁹
DYRK2	Dual-specificity tyrosine-phosphorylation regulated kinase 2	Kinase	0.00265	0.21174	No Involvement in DILI	
EGFR	Epidermal growth factor receptor erbB1	Kinase	0.00147	0.55702	No Involvement in DILI	

EIF2AK4	Eukaryotic translation initiation factor 2-alpha kinase 4	Kinase	0.00248	0.04233	Regulation of acute and chronic liver injury	Arriazu, E. et al. (2013) ¹⁰
ESRRA	Estrogen-related receptor alpha	NHR	0.00091	0.34558	Loss of activity promotes hepatocellular carcinoma	Eui-Ju Hong, E.-J. et al. (2013) ¹¹
FABP4	Fatty acid binding protein adipocyte	Transporter	0.00063	0.30870	Not usually expressed in liver, expressed by hepatocellular carcinoma cells	Thompson, K. J. et al. (2018) ¹²
FBP1	Fructose-1	6-bisphosphatase	0.00246	-0.12770	No Involvement in DILI	
FGR	Tyrosine-protein kinase FGR	Kinase	0.00291	0.13935	No Involvement in DILI	
MAPK11	MAP kinase p38 beta	Kinase	0.00593	0.28874	Cellular stress response (Autophagy/Oxidative stress)	Yang, X. et al. (2015) ¹³ ; Huang, Y. et al. (2019) ¹⁴
MPL	Thrombopoietin receptor	Other	0.00392	0.23564	No Involvement in DILI	
NCOA2	Peroxisome proliferator-activated receptor gamma/Nuclear receptor coactivator 2	Other	0.00079	0.48584	No Involvement in DILI	
NQO2	Quinone reductase 2	Oxidoreductases	0.00300	0.38398	Oxidative stress	Miettinen, T.P. et al. (2014) ¹⁵
P4HTM	Hypoxia-inducible factor prolyl 4-hydroxylase	Other	0.00286	0.01138	Inactivation has a protective role for alcohol induced liver damages	Laitakari, A. et al. (2019) ¹⁶
PLA2G1B	Phospholipase A2 group 1B	Hydrolases	0.00148	0.67637	Protection against Fas-induced liver injuries	Li, G. et al. (2011) ¹⁷
PRKAB1	AMP-activated protein kinase	beta-1 subunit	0.00340	0.19311	Protective role in liver regeneration	Huang, J. et al. (2018) ¹⁸
PRNP	Prion protein	Other	0.00082	0.43342	No Involvement in DILI	
PTGES	Prostaglandin E synthase	Isomerases	0.00330	0.15025	Inhibitors cause severe DILI	Jin, Y. et al. (2018) ¹⁹ ; Norman, et al. B.H. (2018) ²⁰
RARG	Retinoic acid receptor gamma	NHR	0.00153	0.32604	Higher expression in nonalcoholic steatohepatitis	Erin E. E. et al. (2018) ²¹
RPS6KA6	Ribosomal protein S6 kinase alpha 6	Kinase	0.00053	0.41260	Prevention and treatment of liver injuries and fibrosis	Buck, M. et al. (2008) ²²
TBXAS1	Thromboxane-A synthase	Isomerases	0.00071	0.45820	Production of hepatic injury during hepatic stress	Yokoama, Y. et al. (2005) ²³

1. Chiang, D. J. *et al.* Adenosine 2A Receptor Antagonist Prevented and Reversed Liver Fibrosis in a Mouse Model of Ethanol-Exacerbated Liver Fibrosis. *PLoS ONE* **8**, e69114 (2013).
2. Ahmed, M. M., Al-Obosi, J., Osman, H. & Shayoub, M. Overexpression of Aldose Reductase Render Mouse Hepatocytes More Sensitive to Acetaminophen Induced Oxidative Stress and Cell Death. *Indian J. Clin. Biochem.* **31**, 162–170 (2016).
3. Barski, O. A., Tipparaju, S. M. & Bhatnagar, A. The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification. *Drug Metab. Rev.* **40**, 553–624 (2008).
4. Chen, W.-D. & Zhang, Y. Regulation of aldo–keto reductases in human diseases. *Front. Pharmacol.* **3**, 35 (2012).
5. Sutti, S. & Tacke, F. Liver inflammation and regeneration in drug-induced liver injury: sex matters! *Clin. Sci.* **132**, 609–613 (2018).
6. Lu, X. *et al.* Induction of cyclin mRNA and cyclin-associated histone H1 kinase during liver regeneration. *J. Biol. Chem.* **267**, 2841–2844 (1992).
7. Xu, X. *et al.* Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. *Clin. Cancer Res.* **9**, 1764–1772 (2003).
8. Zimmermann, H. W. *et al.* Interleukin-8 Is Activated in Patients with Chronic Liver Diseases and Associated with Hepatic Macrophage Accumulation in Human Liver Fibrosis. *PLoS ONE* **6**, e21381 (2011).
9. Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol. Ther.* **138**, 103–141 (2013).
10. Arriazu, E. *et al.* GCN2 kinase is a key regulator of fibrogenesis and acute and chronic liver injury induced by carbon tetrachloride in mice. *Lab. Invest.* **93**, 303–310 (2013).
11. Hong, E.-J., Levasseur, M.-P., Dufour, C. R., Perry, M.-C. & Giguère, V. Loss of estrogen-related receptor α promotes hepatocarcinogenesis development via metabolic and inflammatory disturbances. *Proc. Natl. Acad. Sci.* **110**, 17975–17980 (2013).
12. Thompson, K. J. *et al.* Altered fatty acid-binding protein 4 (FABP 4) expression and function in human and animal models of hepatocellular carcinoma. *Liver Int.* **38**, 1074–1083 (2018).
13. Yang, X. *et al.* Autophagy protects against dasatinib-induced hepatotoxicity via p38 signaling.

Oncotarget **6**, 6203 (2015).

14. Huang, Y. *et al.* The Increase of ROS Caused by the Interference of DEHP with JNK/p38/p53 Pathway as the Reason for Hepatotoxicity. *Int. J. Environ. Res. Public. Health* **16**, 356 (2019).
15. Miettinen, T. P. & Björklund, M. NQO2 Is a Reactive Oxygen Species Generating Off-Target for Acetaminophen. *Mol. Pharm.* **11**, 4395–4404 (2014).
16. Laitakari, A. *et al.* Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease. *Redox Biol.* **22**, 101145 (2019).
17. Li, G., Chen, W., Han, C. & Wu, T. Cytosolic phospholipase A2 α protects against Fas-but not LPS-induced liver injury. *J. Hepatol.* **55**, 1281–1290 (2011).
18. Huang, J. *et al.* Potential roles of AMP-activated protein kinase in liver regeneration in mice with acute liver injury. *Mol. Med. Rep.* (2018) doi:10.3892/mmr.2018.8522.
19. Jin, Y. *et al.* Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor. *Br. J. Clin. Pharmacol.* **84**, 179–188 (2018).
20. Norman, B. H. *et al.* Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury. *J. Med. Chem.* **61**, 2041–2051 (2018).
21. Elbel, E. E. *et al.* Hepatic nuclear receptor expression associates with features of histology in pediatric nonalcoholic fatty liver disease. *Hepatol. Commun.* **2**, 1213–1226 (2018).
22. Buck, M. Targeting ribosomal S-6 kinase for the prevention and treatment of liver injury and liver fibrosis. *Drug News Perspect.* **21**, 301–306 (2008).
23. Yokoyama, Y., Nimura, Y., Nagino, M., Bland, K. I. & Chaudry, I. H. Role of thromboxane in producing hepatic injury during hepatic stress. *Arch. Surg.* **140**, 801–807 (2005).